Herve Yves Sroussi, D.M.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Calgranulin A | 7 | 2012 | 80 | 2.070 |
Why?
|
Lichen Planus, Oral | 8 | 2023 | 56 | 1.780 |
Why?
|
Xerostomia | 5 | 2021 | 94 | 1.480 |
Why?
|
Calgranulin B | 5 | 2011 | 86 | 1.350 |
Why?
|
Stomatognathic Diseases | 2 | 2020 | 22 | 1.340 |
Why?
|
Papillomavirus Infections | 5 | 2023 | 1602 | 1.120 |
Why?
|
Head and Neck Neoplasms | 5 | 2023 | 2881 | 1.100 |
Why?
|
Salivation | 2 | 2017 | 22 | 1.100 |
Why?
|
Mouth Diseases | 3 | 2020 | 238 | 1.070 |
Why?
|
Mouth Neoplasms | 9 | 2024 | 593 | 1.030 |
Why?
|
Neutrophils | 9 | 2021 | 3756 | 0.920 |
Why?
|
Sjogren's Syndrome | 3 | 2015 | 234 | 0.920 |
Why?
|
Oropharyngeal Neoplasms | 3 | 2023 | 491 | 0.860 |
Why?
|
Dental Caries | 5 | 2023 | 420 | 0.830 |
Why?
|
Stomatitis | 3 | 2022 | 271 | 0.820 |
Why?
|
Leukocyte L1 Antigen Complex | 2 | 2012 | 93 | 0.780 |
Why?
|
Candidiasis, Oral | 3 | 2012 | 57 | 0.770 |
Why?
|
Oncogene Proteins, Viral | 1 | 2023 | 342 | 0.760 |
Why?
|
Acromegaly | 1 | 2024 | 306 | 0.740 |
Why?
|
Temporomandibular Joint Disorders | 1 | 2024 | 220 | 0.730 |
Why?
|
Oral Hygiene | 2 | 2022 | 129 | 0.720 |
Why?
|
HIV Seropositivity | 2 | 2018 | 960 | 0.670 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2024 | 4019 | 0.670 |
Why?
|
Neutrophil Activation | 2 | 2010 | 180 | 0.660 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 218 | 0.650 |
Why?
|
Diagnosis, Oral | 1 | 2018 | 23 | 0.640 |
Why?
|
Heart Valves | 1 | 2020 | 284 | 0.630 |
Why?
|
Anti-Inflammatory Agents | 3 | 2020 | 1795 | 0.600 |
Why?
|
Coronavirus | 1 | 2020 | 149 | 0.600 |
Why?
|
Periodontal Attachment Loss | 1 | 2018 | 144 | 0.590 |
Why?
|
Dental Care for Chronically Ill | 2 | 2007 | 32 | 0.590 |
Why?
|
Osteoradionecrosis | 1 | 2017 | 51 | 0.580 |
Why?
|
Sensation Disorders | 1 | 2017 | 160 | 0.550 |
Why?
|
Vitamin D Deficiency | 2 | 2018 | 1377 | 0.510 |
Why?
|
Poloxamer | 1 | 2015 | 56 | 0.500 |
Why?
|
Salivary Glands | 2 | 2015 | 229 | 0.500 |
Why?
|
Dimethylpolysiloxanes | 1 | 2015 | 142 | 0.480 |
Why?
|
Periodontal Diseases | 1 | 2017 | 451 | 0.450 |
Why?
|
Dexamethasone | 2 | 2022 | 1927 | 0.440 |
Why?
|
Tolonium Chloride | 2 | 2015 | 23 | 0.430 |
Why?
|
Vitamin D | 2 | 2020 | 3282 | 0.420 |
Why?
|
Heart Valve Diseases | 1 | 2020 | 1033 | 0.410 |
Why?
|
Receptor, PAR-2 | 1 | 2011 | 33 | 0.400 |
Why?
|
Precancerous Conditions | 3 | 2024 | 977 | 0.400 |
Why?
|
Leukoplakia, Oral | 4 | 2024 | 77 | 0.390 |
Why?
|
Oxidation-Reduction | 7 | 2012 | 2223 | 0.380 |
Why?
|
Preoperative Care | 1 | 2020 | 2246 | 0.380 |
Why?
|
Endotoxemia | 1 | 2012 | 196 | 0.380 |
Why?
|
Surgical Wound Infection | 1 | 2020 | 1521 | 0.370 |
Why?
|
Coloring Agents | 2 | 2015 | 559 | 0.350 |
Why?
|
Oligopeptides | 2 | 2012 | 1184 | 0.350 |
Why?
|
Communicable Diseases | 1 | 2017 | 876 | 0.320 |
Why?
|
Salivary Gland Diseases | 1 | 2007 | 37 | 0.290 |
Why?
|
Fluoresceins | 3 | 2011 | 234 | 0.270 |
Why?
|
Candida albicans | 1 | 2008 | 373 | 0.260 |
Why?
|
DNA, Viral | 2 | 2023 | 2195 | 0.250 |
Why?
|
Reactive Oxygen Species | 2 | 2010 | 2127 | 0.250 |
Why?
|
Wound Healing | 3 | 2014 | 2781 | 0.250 |
Why?
|
Adenosine | 1 | 2010 | 802 | 0.250 |
Why?
|
Tacrolimus | 2 | 2022 | 733 | 0.250 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3603 | 0.240 |
Why?
|
Chemotaxis, Leukocyte | 2 | 2011 | 663 | 0.240 |
Why?
|
Down-Regulation | 1 | 2011 | 2901 | 0.230 |
Why?
|
Methionine | 1 | 2006 | 569 | 0.230 |
Why?
|
Burning Mouth Syndrome | 1 | 2024 | 25 | 0.230 |
Why?
|
Antifungal Agents | 1 | 2008 | 749 | 0.220 |
Why?
|
CD4 Lymphocyte Count | 2 | 2007 | 2569 | 0.220 |
Why?
|
Endocarditis, Bacterial | 1 | 2007 | 442 | 0.210 |
Why?
|
Administration, Topical | 3 | 2022 | 696 | 0.210 |
Why?
|
Lichenoid Eruptions | 1 | 2022 | 13 | 0.210 |
Why?
|
Lipopolysaccharides | 4 | 2012 | 2203 | 0.210 |
Why?
|
Recombinant Proteins | 5 | 2011 | 6525 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3077 | 0.210 |
Why?
|
HIV Infections | 5 | 2011 | 17270 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3197 | 0.200 |
Why?
|
Cyclosporins | 1 | 2022 | 216 | 0.200 |
Why?
|
Antibiotic Prophylaxis | 1 | 2007 | 640 | 0.200 |
Why?
|
Oral Medicine | 1 | 2021 | 36 | 0.190 |
Why?
|
Root Caries | 1 | 2021 | 16 | 0.190 |
Why?
|
Human papillomavirus 16 | 1 | 2023 | 266 | 0.190 |
Why?
|
Mucositis | 1 | 2022 | 108 | 0.190 |
Why?
|
Dysgeusia | 1 | 2020 | 15 | 0.180 |
Why?
|
Graft vs Host Disease | 3 | 2023 | 3024 | 0.180 |
Why?
|
Quality of Life | 3 | 2024 | 13263 | 0.180 |
Why?
|
Humans | 46 | 2024 | 757566 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8600 | 0.170 |
Why?
|
Mutation, Missense | 1 | 2008 | 2564 | 0.170 |
Why?
|
Sepsis | 1 | 2012 | 2579 | 0.160 |
Why?
|
Education, Distance | 1 | 2021 | 259 | 0.150 |
Why?
|
Inflammation Mediators | 1 | 2006 | 1879 | 0.150 |
Why?
|
Chicago | 1 | 2018 | 254 | 0.140 |
Why?
|
Papillomaviridae | 2 | 2022 | 1120 | 0.140 |
Why?
|
Stress, Psychological | 2 | 2012 | 4456 | 0.140 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2011 | 662 | 0.140 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 2 | 2006 | 221 | 0.140 |
Why?
|
Skin | 2 | 2012 | 4464 | 0.130 |
Why?
|
Aged | 16 | 2023 | 167890 | 0.130 |
Why?
|
Middle Aged | 17 | 2024 | 219192 | 0.120 |
Why?
|
Emulsions | 1 | 2015 | 152 | 0.120 |
Why?
|
Enzyme Activation | 2 | 2011 | 3593 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5648 | 0.120 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2008 | 1693 | 0.120 |
Why?
|
Aged, 80 and over | 6 | 2022 | 58558 | 0.110 |
Why?
|
Th1-Th2 Balance | 1 | 2013 | 38 | 0.110 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4159 | 0.110 |
Why?
|
RNA, Neoplasm | 2 | 2013 | 749 | 0.110 |
Why?
|
Survival Rate | 2 | 2020 | 12684 | 0.100 |
Why?
|
Mouth Mucosa | 1 | 2015 | 426 | 0.100 |
Why?
|
Female | 21 | 2024 | 389943 | 0.100 |
Why?
|
Nutrition Surveys | 1 | 2020 | 1716 | 0.100 |
Why?
|
Fluorescent Dyes | 2 | 2010 | 1897 | 0.100 |
Why?
|
Epithelium, Corneal | 1 | 2014 | 249 | 0.100 |
Why?
|
Bacterial Load | 1 | 2012 | 151 | 0.100 |
Why?
|
Keratin-17 | 1 | 2011 | 26 | 0.100 |
Why?
|
Depsipeptides | 1 | 2011 | 95 | 0.090 |
Why?
|
Restraint, Physical | 2 | 2012 | 186 | 0.090 |
Why?
|
Smoking | 3 | 2017 | 9036 | 0.090 |
Why?
|
Inflammation | 2 | 2012 | 10709 | 0.090 |
Why?
|
Cells, Cultured | 4 | 2011 | 18936 | 0.090 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2011 | 1896 | 0.090 |
Why?
|
Superinfection | 1 | 2011 | 63 | 0.090 |
Why?
|
Toll-Like Receptor 4 | 1 | 2014 | 576 | 0.090 |
Why?
|
Case-Control Studies | 3 | 2022 | 22022 | 0.090 |
Why?
|
Radiotherapy | 1 | 2017 | 1498 | 0.090 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2010 | 45 | 0.090 |
Why?
|
Fibrosis | 1 | 2017 | 2038 | 0.090 |
Why?
|
Treatment Outcome | 5 | 2022 | 64242 | 0.090 |
Why?
|
beta 2-Microglobulin | 1 | 2011 | 328 | 0.090 |
Why?
|
Enzyme Activators | 1 | 2010 | 57 | 0.090 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 244 | 0.090 |
Why?
|
Receptors, Purinergic P1 | 1 | 2010 | 108 | 0.090 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2012 | 354 | 0.080 |
Why?
|
Herpesviridae Infections | 1 | 2011 | 270 | 0.080 |
Why?
|
DNA | 1 | 2023 | 7200 | 0.080 |
Why?
|
Steroids | 2 | 2022 | 926 | 0.080 |
Why?
|
Cytodiagnosis | 1 | 2013 | 441 | 0.080 |
Why?
|
Drug Combinations | 1 | 2015 | 2020 | 0.080 |
Why?
|
Time Factors | 3 | 2020 | 39811 | 0.080 |
Why?
|
Male | 16 | 2024 | 358180 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2024 | 12951 | 0.080 |
Why?
|
Leukoplakia, Hairy | 1 | 2007 | 9 | 0.080 |
Why?
|
Stomatitis, Herpetic | 1 | 2007 | 12 | 0.080 |
Why?
|
Adult | 14 | 2023 | 219725 | 0.080 |
Why?
|
Th1 Cells | 1 | 2013 | 1031 | 0.070 |
Why?
|
Adenosine Deaminase | 1 | 2010 | 251 | 0.070 |
Why?
|
Th2 Cells | 1 | 2013 | 1047 | 0.070 |
Why?
|
Warts | 1 | 2007 | 66 | 0.070 |
Why?
|
Voluntary Health Agencies | 1 | 2007 | 38 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2015 | 2425 | 0.070 |
Why?
|
Saliva, Artificial | 1 | 2006 | 4 | 0.070 |
Why?
|
Mutant Proteins | 1 | 2008 | 491 | 0.070 |
Why?
|
Pharmaceutical Vehicles | 1 | 2006 | 57 | 0.070 |
Why?
|
Wound Infection | 1 | 2009 | 243 | 0.070 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2006 | 38 | 0.070 |
Why?
|
Neutrophil Infiltration | 1 | 2009 | 387 | 0.070 |
Why?
|
Muscarinic Agonists | 1 | 2006 | 91 | 0.070 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2006 | 294 | 0.070 |
Why?
|
Prevalence | 2 | 2018 | 15640 | 0.070 |
Why?
|
Sex Factors | 1 | 2020 | 10495 | 0.070 |
Why?
|
Cholinergic Antagonists | 1 | 2006 | 164 | 0.060 |
Why?
|
Prospective Studies | 4 | 2024 | 54092 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 2011 | 854 | 0.060 |
Why?
|
Protein Kinase C | 1 | 2010 | 1199 | 0.060 |
Why?
|
Loss of Heterozygosity | 1 | 2007 | 659 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1925 | 0.060 |
Why?
|
Cell Movement | 4 | 2014 | 5196 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2674 | 0.060 |
Why?
|
Anti-Infective Agents | 1 | 2011 | 981 | 0.060 |
Why?
|
United States | 4 | 2020 | 71902 | 0.060 |
Why?
|
Cohort Studies | 2 | 2020 | 41190 | 0.060 |
Why?
|
Dental Prophylaxis | 1 | 2023 | 28 | 0.060 |
Why?
|
Cranial Irradiation | 1 | 2006 | 390 | 0.060 |
Why?
|
Alanine | 1 | 2006 | 603 | 0.060 |
Why?
|
Chemotaxis | 1 | 2006 | 598 | 0.060 |
Why?
|
Antibodies | 1 | 2011 | 2420 | 0.060 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2004 | 213 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2023 | 79984 | 0.050 |
Why?
|
Dental Restoration, Permanent | 1 | 2023 | 128 | 0.050 |
Why?
|
Paresthesia | 1 | 2024 | 162 | 0.050 |
Why?
|
Fluocinonide | 1 | 2022 | 9 | 0.050 |
Why?
|
Interferon Type I | 1 | 2006 | 562 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2007 | 1177 | 0.050 |
Why?
|
Clobetasol | 1 | 2022 | 33 | 0.050 |
Why?
|
Microbial Sensitivity Tests | 1 | 2008 | 1943 | 0.050 |
Why?
|
Erythema | 1 | 2023 | 262 | 0.050 |
Why?
|
Triamcinolone | 1 | 2022 | 68 | 0.050 |
Why?
|
Risk Factors | 4 | 2017 | 73708 | 0.050 |
Why?
|
Canada | 1 | 2007 | 2109 | 0.050 |
Why?
|
Cysteine | 1 | 2006 | 892 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10749 | 0.050 |
Why?
|
Cytokines | 2 | 2014 | 7336 | 0.050 |
Why?
|
Animals | 8 | 2021 | 167718 | 0.050 |
Why?
|
Point Mutation | 1 | 2006 | 1594 | 0.050 |
Why?
|
Mice | 5 | 2014 | 81066 | 0.050 |
Why?
|
Piperazines | 1 | 2011 | 2511 | 0.050 |
Why?
|
Dentin | 1 | 2021 | 74 | 0.050 |
Why?
|
Streptococcus mutans | 1 | 2021 | 98 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7584 | 0.050 |
Why?
|
Rats | 2 | 2006 | 23676 | 0.040 |
Why?
|
Biopsy | 2 | 2013 | 6757 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2011 | 13442 | 0.040 |
Why?
|
Peptides | 1 | 2011 | 4338 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2023 | 426 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 25924 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 3709 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2687 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 17615 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3164 | 0.040 |
Why?
|
Pain | 2 | 2024 | 5063 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12047 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 386 | 0.040 |
Why?
|
Logistic Models | 1 | 2012 | 13221 | 0.040 |
Why?
|
Kidney | 1 | 2012 | 7012 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 4565 | 0.030 |
Why?
|
Liver | 1 | 2012 | 7502 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15781 | 0.030 |
Why?
|
Chronic Disease | 2 | 2022 | 9263 | 0.030 |
Why?
|
Wounds and Injuries | 1 | 2009 | 2475 | 0.030 |
Why?
|
Pain Measurement | 1 | 2006 | 3523 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2006 | 5861 | 0.030 |
Why?
|
Luminescence | 1 | 2015 | 108 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18114 | 0.030 |
Why?
|
Cattle | 1 | 2021 | 3846 | 0.030 |
Why?
|
Dental Implants | 1 | 2023 | 790 | 0.030 |
Why?
|
Cell Migration Assays | 1 | 2014 | 21 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2023 | 4808 | 0.030 |
Why?
|
Toll-Like Receptor 1 | 1 | 2014 | 47 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2004 | 2621 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2022 | 2691 | 0.030 |
Why?
|
Lung | 1 | 2012 | 9973 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2014 | 426 | 0.030 |
Why?
|
Chemokine CXCL1 | 1 | 2014 | 101 | 0.030 |
Why?
|
Areca | 1 | 2013 | 11 | 0.030 |
Why?
|
Decision Making | 1 | 2007 | 3909 | 0.030 |
Why?
|
HIV-1 | 1 | 2011 | 6850 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2007 | 7796 | 0.030 |
Why?
|
Pilot Projects | 1 | 2006 | 8550 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 477 | 0.030 |
Why?
|
Mice, Hairless | 1 | 2012 | 39 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2014 | 630 | 0.030 |
Why?
|
Pertussis Toxin | 1 | 2011 | 176 | 0.020 |
Why?
|
Debridement | 1 | 2014 | 492 | 0.020 |
Why?
|
Respiratory Burst | 1 | 2011 | 110 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 684 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3839 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2014 | 696 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1704 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2011 | 818 | 0.020 |
Why?
|
Herpesviridae | 1 | 2011 | 106 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3354 | 0.020 |
Why?
|
Child | 2 | 2007 | 79782 | 0.020 |
Why?
|
Health Care Costs | 1 | 2022 | 3234 | 0.020 |
Why?
|
Young Adult | 4 | 2021 | 58755 | 0.020 |
Why?
|
Curriculum | 1 | 2021 | 3715 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4641 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15207 | 0.020 |
Why?
|
Aging | 1 | 2006 | 8654 | 0.020 |
Why?
|
Cricetinae | 1 | 2011 | 2427 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3799 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2013 | 12761 | 0.020 |
Why?
|
Adolescent | 3 | 2014 | 87819 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5031 | 0.020 |
Why?
|
Cell Line | 2 | 2014 | 15587 | 0.020 |
Why?
|
Focus Groups | 1 | 2011 | 1380 | 0.020 |
Why?
|
ROC Curve | 1 | 2013 | 3562 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2017 | 1821 | 0.020 |
Why?
|
Isoproterenol | 1 | 2004 | 394 | 0.010 |
Why?
|
Actins | 1 | 2011 | 2048 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2011 | 1787 | 0.010 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 107 | 0.010 |
Why?
|
Virus Replication | 1 | 2011 | 2430 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2014 | 3043 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2014 | 3664 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3317 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10405 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21217 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14637 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9403 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8503 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11890 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 21990 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12092 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20037 | 0.010 |
Why?
|